

**INFORMATION
DISCLOSURE
STATEMENT**



Atty. Docket No.: 275.00030102	Serial No.: 10/038,984
Applicant(s): LI et al.	Confirmation No.: 9705
Application Filing Date: 01/04/02	Group: 1635
Information Disclosure Statement mailed:	March 8, 2005

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
TV	✗	5,580,859	12/03/96	Felgner et al.			
↓	✗	5,624,803	04/29/97	Noonberg et al.			
↓	✗	5,631,148	05/20/97	Urdea			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
TV	✗	1994/01550	01/20/94	WO				
↓	✗	1995/15378	06/08/95	WO				
↓	✗	1997/11170	3/27/97	WO				

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
TV	✗	Adams, "RNA Therapeutics Enter Clinical Trials," (2005) The Scientist, Vol.19, Issue 1. Retrieved from the Internet on 01/18/05. Retrieved as http://www.the-scientist.com/2005/1/17/28/1 6 pages
↓	✗	Andino, "RNAi puts a lid on virus replication," (2003) Nature Biotechnology, Vol. 21, No.6, pgs. 629-630
↓	✗	Caplen, "RNAi quashes polyQ," (2004) Nature Medicine, Vol.10, No. 8, pgs. 775-776
↓	✗	Check, "Hopes rise for RNA therapy as mouse study hits target," (2004) Nature, Vol. 432, pg. 136
↓	✗	Dorland's Illustrated Medical Dictionary, (2000) 29 th Edition, page 1140
↓	✗	Heidel et al., "Lack of interferon response in animals to naked siRNAs," (2004) Nature Biotechnology, Vol. 22, No. 12, pgs. 1579-1582
↓	✗	McCaffrey et al., "RNA Interference in Adult Mice," (2002) Nature, Vol. 418, pgs. 38-39

EXAMINER

Date Considered

6/9/05

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.00030102	Serial No.: 10/038,984
	Applicant(s): LI et al.	Confirmation No.: 9705
	Application Filing Date: 01/04/02	Group: 1635
	Information Disclosure Statement mailed: <u>March 8</u> , 2005	

Examiner Initial	Copy Enclosed	Document Description
TV	✗	McCaffrey et al., "Inhibition of hepatitis B virus in mice by RNA interference," (2003) Nature Biotechnology, Vol. 21, No. 6, pgs. 639-644
	✗	<u>News Release</u> . "Acuity Pharmaceuticals Closes \$15 Million Financing and Initiates First-Ever Clinical Trial of an RNAi Therapeutic," Philadelphia, October 7/PRNewswire, retrieved from the Internet. Retrieved as http://www.biospace.com/news_story.cfm?StoryID=17599420&full=1&print=1 (1 of 3) 1/31/2005 11:10:52 a.m. 2 pages
	✗	<u>News Release</u> . Sirna Therapeutics. "Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at Cleveland Clinic," Boulder, Colo., Nov 23/PRNewswire. Retrieved from the Internet. Retrieved as http://phx.corporate-ir.net/phoenix.zhtml?c=141787&p=irol-newsArticle&ID=646830&highlight= (1 of 4) 01/31/05 11:16:03 AM, 4 pages
	✗	<u>News Release</u> . Sirna Therapeutics. "Sirna Therapeutics and Targeted Genetics Form Huntington's Disease Collaboration," Boulder, Colo. and Seattle, Jan. 11/PRNewswire. Retrieved from the Internet. Retrieved as http://phx.corporate-ir.net/phoenix.zhtml?c=141787&p=irol-newsArticle&ID=661337&highlights= (1 of 4) 01/31/05 11:14:20 AM, 4 pages
	✗	Rossi, "A Cholesterol Connection in RNAi," (2004) Nature, Vol. 432, pgs. 155-156
	✗	Soutschek et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," (2004) Nature, Vol. 432, pgs. 173-178
	✗	ZFIN - The Zebrafish Model Organism Database. Database Information Sheet. Copyright © University of Oregon, 1994-2005, Eugene, Oregon. Retrieved from the Internet on 03/07/05. http://zfin.org/zf_info/dbase/db.html , 2 pages.
↓	✗	Xi et al., "RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia," (2004) Nature Medicine, Vol.10, No. 8, pgs. 816-820

EXAMINER 	Date Considered <u>6/9/05</u>
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	